ConSynance doses first patient in Phase 2a PWS trial of CSTI-500

ConSynance Therapeutics has dosed the first participant in a Phase 2a clinical trial of CSTI-500, its investigational small-molecule treatment for Prader-Willi syndrome (PWS). The study, conducted at Vanderbilt University Medical Center, is an open-label proof-of-concept trial enrolling approximately 12 individuals aged 13 to 50 years.

CSTI-500 is an orally administered triple monoamine reuptake inhibitor designed to raise levels of serotonin, dopamine, and norepinephrine simultaneously. The rationale is that modulating all three neurotransmitters in combination may address the interrelated symptoms of hyperphagia and neurobehavioural disturbance that define the condition's most burdensome features. Participants will receive individualised doses for around 84 days, with dosing guided by a pharmacokinetic model intended to optimise target engagement. The primary objectives are safety and tolerability, with exploratory efficacy measures focused on hyperphagia and neurobehavioural symptoms using validated clinical tools.

Clinical background

The programme has accumulated a meaningful early-stage safety dataset. CSTI-500 has been evaluated in multiple Phase 1 studies involving nearly 100 participants, including individuals with PWS. Those studies established a favourable safety profile, and central nervous system target engagement was confirmed through positron emission tomography imaging, providing mechanistic support for the Phase 2 step-up.

Shuang Liu, founder and chief executive of ConSynance, said the study would allow the company to gather early data on the drug's potential to improve hyperphagia and, "more notably, the related neurobehavioural symptoms commonly experienced by this population." The trial is partly funded through venture philanthropy from the Foundation for Prader-Willi Research (FPWR), which has backed several clinical-stage PWS programmes over the years. FPWR notes that one investment it supported ultimately yielded an FDA-approved treatment in the indication, lending credibility to the philanthropic model as a capital-efficient pathway for rare-disease development.

Market context and competitive landscape

PWS affects roughly 1 in 15,000 live births and carries a significant unmet medical need, particularly around hyperphagia and the psychiatric and behavioural comorbidities that place severe strain on families and caregivers. Registry data cited by FPWR consistently identify behavioural outbursts as among the most difficult daily challenges for affected families, a burden that approved growth hormone therapy does not address.

The PWS therapeutic landscape has attracted a handful of companies pursuing different mechanistic approaches. Peptide-based strategies targeting oxytocin and melanocortin pathways have been explored, alongside carbetocin and diazoxide choline programmes, with varying degrees of late-stage clinical success. ConSynance's triple-reuptake approach is mechanistically distinct from most of these, positioning CSTI-500 to potentially address neurobehavioural symptoms more directly than metabolic or hypothalamic-targeting agents. Whether that translational hypothesis holds in the Phase 2a dataset will be the key near-term question for the field.

The small enrolment size of the current study reflects its proof-of-concept design; 12 participants will generate signal rather than statistical power. Investors and clinical observers will be watching for any early indication of effect on validated neurobehavioural scales and for confirmation that the individualised dosing strategy is operationally robust. A clean safety read and a directional efficacy signal would support progression to a larger, controlled Phase 2b study, which ConSynance has not yet announced or described in publicly available materials.